Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Ross

Ophthalmology Allentown, PA Medical Doctor

NPI 1609876994 CMS profile 253892

1739 W Fairmont St, Allentown, PA 18104

Open in the dashboard

General payments

$3,650

183 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Ross of Allentown, PA is reported in the CMS Open Payments database as having received $3,650 across 183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $727 33
2024 General $753 33
2023 General $565 23
2022 General $475 26
2021 General $575 33
2020 General $182 12
2019 General $373 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Ross
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Daniel Ross were reported at $727. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Daniel Ross Ophthalmology median Middle half National median
2019 $373 $258 $104–$655 $163
2020 $182 $126 $45–$321 $114
2021 $575 $205 $76–$534 $132
2022 $475 $266 $100–$678 $149
2023 $565 $308 $117–$745 $160
2024 $753 $340 $127–$846 $164
2025 $727 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $432 24 payments
  2. EyePoint Pharmaceuticals US, Inc. $346 10 payments
  3. Alcon Vision LLC $345 19 payments
  4. Sun Pharmaceutical Industries Inc. $268 13 payments
  5. Genentech USA, Inc. $229 13 payments
  6. Regeneron Healthcare Solutions, Inc. $191 11 payments
  7. Allergan Inc. $177 11 payments
  8. Cardinal Health 110, LLC $150 1 payment
  9. Alimera Sciences, Inc. $140 7 payments
  10. Omeros Corporation $123 7 payments
  11. Other $1,250 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,500 182 payments
  2. Consulting Fee $150 1 payment
Products named General payments · program years 2019–2025
  1. OZURDEX $311 11 payments
  2. YUTIQ $292 7 payments
  3. Cequa $227 11 payments
  4. Omidria $157 9 payments
  5. VABYSMO $144 8 payments
  6. Clareon $141 7 payments
  7. XIIDRA $118 8 payments
  8. ILUVIEN $115 5 payments
  9. Syfovre $101 4 payments
  10. Xelpros $96 5 payments
  11. Other $2,124 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,531

Median for Ophthalmology: 891

Drug cost

$260,503

Median for Ophthalmology: $68,233

Branded share of claims

50.4%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 135 $80,522
Restasis Cyclosporine Brand 53 $75,064
Eylea Aflibercept Brand 12 $22,510
Xiidra Lifitegrast Brand 11 $21,342
Rocklatan Netarsudil Mesylat/Latanoprost Brand 35 $14,856
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 38 $9,061
Combigan Brimonidine Tartrate/Timolol Brand 16 $8,418
Latanoprost Generic 479 $7,479
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 304 $6,325
Brimonidine Tartrate Generic 68 $3,978

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$646,894

Of which drugs: $404,472

Medicare patients

1,037

Average age 75

Services billed

15,179

580 women, 457 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 48%
Arthritis 45%
Chronic kidney disease 39%
Ischemic heart disease 27%
Atrial fibrillation 20%
Depression 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, faricimab-svoa, 0.1 mg J2777 Office 52 10,260 $280,093
Injection, dexamethasone, intravitreal implant, 0.1 mg J7312 Office 15 126 $20,231
Injection, bevacizumab, 10 mg J9035 Office 27 80 $4,477

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OZURDEX
  • AbbVie, Inc. $140
$140 — 126
Syfovre
  • Apellis Pharmaceuticals, Inc. $73
$73 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $55
$55 — —
VABYSMO
  • Genentech USA, Inc. $44
$44 — 10,260
Izervay
  • Astellas Pharma US Inc $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record